CRISPR Applications in Medicine: From Gene Therapy to Disease Treatment

Editing the Code of Life

In December 2023, the US Food and Drug Administration approved Casgevy — the world's first CRISPR-based medicine — for treatment of sickle cell disease and transfusion-dependent beta-thalassemia. For patients who previously faced lifelong pain crises or regular blood transfusions, a single treatment offers the prospect of functional cure. The drug's approval marked a turning point: CRISPR had moved from a laboratory curiosity to a clinical reality in just over a decade since its mechanism was first described.

CRISPR — Clustered Regularly Interspaced Short Palindromic Repeats — was discovered not in a biotech lab but in the immune systems of bacteria. Jennifer Doudna at UC Berkeley and Emmanuelle Charpentier at Umeå University demonstrated in 2012 that this bacterial defense mechanism could be repurposed as a programmable gene-editing tool. They won the Nobel Prize in Chemistry in 2020 for the discovery that has since reshuffled medicine's treatment landscape.

How CRISPR-Cas9 Works

The CRISPR-Cas9 system has two main components. First, a guide RNA (gRNA): a short synthetic RNA molecule designed to match a specific 20-nucleotide sequence in the target genome. Second, the Cas9 protein: a molecular scissors that follows the guide RNA to its target and cuts both strands of the DNA double helix.

Once the double-strand break is made, the cell's own DNA repair machinery takes over. Two pathways are available. Non-Homologous End Joining (NHEJ) is error-prone — it glues the ends back together but often inserts or deletes nucleotides, disrupting the gene. This is used to knock out a gene. Homology-Directed Repair (HDR) uses a provided DNA template to repair the break accurately, allowing a specific sequence to be inserted or corrected. HDR is the basis for gene correction therapies.

CRISPR Variants Beyond Basic Cutting

• Base editing: uses a catalytically impaired Cas9 fused to a chemical enzyme that converts one DNA base to another without making double-strand breaks. David Liu's lab at Harvard Broad Institute developed C-to-T and A-to-G base editors that correct point mutations with high precision.
• Prime editing: described by Liu's lab in 2019, uses a modified reverse transcriptase to write new genetic information directly into the genome — a more versatile approach called a "search and replace" for DNA.
• CRISPRi/CRISPRa: dead Cas9 (dCas9) fused to gene regulators can silence or amplify gene expression without cutting DNA, enabling functional studies and potential therapies targeting gene regulation.
• Cas12a, Cas13: alternative CRISPR proteins that target DNA or RNA with different properties — useful for diagnostics and antiviral applications.

Clinical Applications: What's Approved or in Trials

The Casgevy mechanism is particularly elegant. Sickle cell disease is caused by a point mutation in the adult hemoglobin (HBB) gene. Rather than correcting this mutation directly, the therapy knocks out BCL11A — a repressor that normally silences fetal hemoglobin (HbF) production after birth. With BCL11A inactivated, patients resume producing fetal hemoglobin, which doesn't sickle and functionally compensates for the defective adult form. Clinical trials showed that 29 of 29 evaluable patients were free of vaso-occlusive crises for at least 12 months post-treatment.

Cancer Treatment: CAR-T Cells and Tumor Targeting

Cancer immunotherapy took a major step forward when CRISPR enabled the engineering of allogeneic CAR-T cells — T cells from healthy donors that can be given to any patient, rather than requiring individualized manufacturing from each patient's own blood. This addresses a critical bottleneck: current autologous CAR-T manufacturing takes weeks and costs $400,000–500,000 per patient.

CRISPR edits donor T cells in three ways: inserting the chimeric antigen receptor (CAR) gene, knocking out the T cell receptor (to prevent graft-versus-host disease), and knocking out CD52 or PD-1 to improve persistence. Early clinical results in relapsed ALL patients who had failed all other treatments showed complete remission in several cases — remarkable outcomes that would be impossible with unedited donor cells.

In Vivo Editing: Reaching Tissues Inside the Body

Early CRISPR therapies work ex vivo — cells are removed from the patient, edited in the lab, and reinfused. More ambitious is in vivo editing — delivering CRISPR components directly into the body so editing occurs in target tissues without removing cells.

Intellia Therapeutics achieved a landmark in 2021: a single intravenous infusion of lipid nanoparticles carrying Cas9 mRNA and guide RNA reduced circulating transthyretin protein by 87% in patients with hereditary amyloidosis. This was the first published clinical evidence that CRISPR could edit genes inside the human body after systemic delivery. The liver is currently the most accessible target because it efficiently captures lipid nanoparticles from the bloodstream.

• Eye diseases (Leber congenital amaurosis) are being treated by subretinal injection of CRISPR components — the eye's immune privilege makes it a favorable target.
• Lung diseases require aerosol or lipid nanoparticle delivery to airway epithelium; multiple groups are targeting cystic fibrosis mutations.
• Brain delivery remains technically challenging due to the blood-brain barrier; engineered viral vectors (AAV serotypes) are being optimized for CNS CRISPR delivery.

Safety, Ethics, and the He Jiankui Case

CRISPR's power raises profound ethical questions. Off-target edits — cuts at unintended genomic locations — can cause insertional mutations, potentially activating oncogenes. Modern base editing and prime editing significantly reduce off-target rates, but complete elimination has not been achieved. All current human trials use strict eligibility criteria and long-term follow-up requirements.

The most contentious application is germline editing — altering embryos so that changes are inherited by all future offspring. In 2018, Chinese biophysicist He Jiankui announced he had created the first CRISPR-edited babies by modifying embryos to confer HIV resistance. The experiment was widely condemned by the scientific community as premature and ethically unjustifiable. He was convicted of illegal medical practice in China and sentenced to three years in prison. International scientific bodies, including the WHO and national academies of science, have called for a moratorium on heritable human genome editing until safety and ethical frameworks are established.

The contrast between He's reckless experiment and the careful clinical development of Casgevy defines the field's central tension: CRISPR's therapeutic potential is immense, but the same tool that can cure sickle cell disease could, in irresponsible hands, alter the human germline in ways that affect generations not yet born. The governance of that power is as important as the science itself.